zofenopril 30 to 60 mg/day once daily was as effective as atenolol 50 to 100 mg/day, amlodipine 5 to 10 mg/day and enalapril 20 to 40 mg/day when assessed by reductions in diastolic BP.

Like most people who have been diagnosed with a life-threatening disease, Ruel Bautista is still trying to come to terms with ...

(12.5-25.0 mg/day) and treatment with each of three other types of antihypertensive drugs -- a calcium-channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and a ...

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

The U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Evrysdi (risdiplam), an approved oral ...